Material safety data sheet

Material Safety Data Sheet

Date Prepared: 10/17/03
X-Gen Pharmaceuticals
Prepared
Technical Assistance: 607-562-2700
Big Flats, NY 14814
PROGESTERONE
IDENTIFICATION

EMERGENCY OVERVIEW - Reproductive Hazard. WARNING: As a progestin, this material is a
possible human carcinogen.

Common Name: Progesterone
Chemical Name: Pregn-4-ene-3,20-dione
Synonym: Corpus luteum hormone
Formula: C21H30O2
CAS Number: 57-83-0
RTECS Number: TW0175000
Chemical Family: A Steroid
Therapeutic Category: Progestin
INGREDIENT INFORMATION

Principle Components
Exposure Limits
HEALTH HAZARD INFORMATION

Usual Adult Dose:
The usual oral adult dose of progesterone (micronized to increase bioavailability)
is 400 mg a day, given cyclically. It is also given by intramuscular injection in doses of 5 to 10 mg a
day.
Adverse Effects: Adverse effects of progestins may include abnormal uterine bleeding, dry mouth,
frequent urination, loss of appetite, unusual thirst, unexplained flow of breast milk, mental
depression, skin rash, abdominal pain, cramping, dizziness, swelling in ankles or feet, headache,
mood changes, nervousness, unusual tiredness or weakness, unusual or rapid weight gain, acne, breast
pain or tenderness, hot flashes, insomnia, loss of sexual desire, loss or gain of hair, brown spots on
skin, and nausea. Possible allergic reaction to material if inhaled, ingested or in contact with skin.
Overdose Effects: Overdose may cause nausea and uterine bleeding.

Acute:
Possible eye, skin and/or respiratory tract irritation.
n/f = not found
PROGESTERONE
HEALTH HAZARD INFORMATION CONTINUED

Chronic:
Possible hypersensitization, changes in menstrual cycle, jaundice, hepatitis, porphyria,
blood clots, and cancer.

Inhalation:
May cause irritation. Avoid inhalation. Remove to fresh air.

Eye:
May cause irritation. Avoid contact. Flush with copious quantities of water.

Skin:
May cause irritation. Avoid contact. Flush with copious quantities of water.

Ingestion:
May cause irritation. Avoid ingestion. Flush out mouth with water

Medical Conditions Aggravated by Exposure:
Hypersensitivity to material, known or suspected
breast cancer, liver disease or tumors, pregnancy, thrombophlebitis or thromboembolic disease, and
uterine or genital bleeding.
Cross Sensitivity: n/f
Pregnancy Comments: Although progesterone has been used to prevent miscarriage in women with
progesterone deficiency, progestins are not recommended for therapeutic use in pregnancy because of
the risk of fetal harm.
Pregnancy Category: D
FIRST AID MEASURES

General: Remove from exposure. Remove contaminated clothing. Persons developing serious
hypersensitivity (anaphylactic) reactions must receive immediate medical attention. If person is not
breathing give artificial respiration. If breathing is difficult give oxygen. Obtain medical attention.
Overdose Treatment: Single acute overdose of progestins will seldom result in toxicity. Supportive
treatment is adequate in most situations. In chronic toxicity, obtain a baseline CBC, hepatic and renal
function tests, and treat symptomatically. [Poisindex 2001]
TOXICOLOGICAL INFORMATION

Oral Rat:
Oral Mouse:
Irritancy Data:
Target Organ(s):
Listed as a Carcinogen? NTP: Yes
IARC: Yes
Other: No
n/f = not found
PROGESTERONE
FIREFIGHTING MEASURES

Flash Point:
n/f
Upper Flammable Limit: n/f
Auto-Ignition Temperature: n/f
Lower Flammable Limit: n/f
Extinguisher Media: Water spray, dry chemical, carbon dioxide or foam as appropriate for
surrounding fire and materials.
Fire and Explosion Hazards: This material is assumed to be combustible. As with all dry powders it
is advisable to ground mechanical equipment in contact with dry material to dissipate the potential
buildup of static electricity.
Firefighting Procedures: As with all fires, evacuate personnel to a safe area. Firefighters should use
self-contained breathing equipment and protective clothing.
PHYSICAL HAZARDS

Conditions to Avoid: Avoid exposure to light.
Incompatibilities: Strong oxidizing agents.
Decomposition Products: When heated to decomposition material emits acrid smoke and irritating
fumes. Emits toxic fumes under fire conditions.
Stable? Yes
Hazardous Polymerization? No
HANDLING / SPILL / DISPOSAL MEASURES

Handling: As a general rule, when handling USP Reference Standards avoid all contact and
inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.

Storage:
Store in tight, light-resistant container as defined in the USP-NF. This material should be
handled and stored per label instructions to ensure product integrity.
Spill Response: Wear approved respiratory protection, chemically compatible gloves and protective
clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing
dust. Wash spill site. Place spillage and all contaminated cleanup materials in a thick plastic
hazardous waste disposal bag or leak proof container and label it CAUTION: HAZARDOUS
CHEMICAL WASTE.
Disposal: Place material in a thick plastic hazardous waste disposal bag or leak proof container and
label it CAUTION: HAZARDOUS CHEMICAL WASTE. Dispose of waste in accordance with all
applicable Federal, State and local laws
n/f = not found
PROGESTERONE
EXPOSURE CONTROLS / PERSONAL PROTECTION
Respiratory Protection: Use a NIOSH approved respirator, if it is determined to be necessary by an
industrial hygiene survey involving air monitoring. In the event that a respirator is not required, an
approved dust mask should be used.
Ventilation: Recommended.
Gloves: Rubber
Eye Protection: Safety
Protective Clothing: Protect exposed skin.
PHYSICAL AND CHEMICAL PROPERTIES

Appearance and Odor: White to creamy white crystalline powder; odorless.
Melting Point: 126 - 131° C
Solubility in Water: Practically
Vapor Density: n/f
Boiling Point: n/f
Evaporation Rate: n/f
Specific Gravity: 1.166
Reactivity in Water: n/f
Vapor Pressure: n/f
% Volatile by Volume: n/f
n/f = not found

Source: http://www.x-genpharmaceuticals.us/Powders/Progesterone%20USP/Progesterone_files/MSDS/Progesterone.pdf

kent-online.de

Reiter-WB Teilnehmer Antwerpen,Julia Bilzen,Kim Böhnke,Marcel Clasen,Emma Dillenberger,Lisa Gottschalk,Angela Grein,Madita Griche,Lena Grundei,Laura Hartmann,Fabian Herbst,Leoni Hörter,Jule Hörter,Kira Huck,Dorian Jumpertz,Darleen Kliem,Geena Kreuzberg,Carolin Kroeber,Regine Kroeber,Saskia Krupp,Julia Kurz,Laura Kurz,Sarah

nippc.org

UNITED STATES OF AMERICA BEFORE THE FEDERAL ENERGY REGULATORY COMMISSION MOTION TO ANSWER AND ANSWER OF EXELON TO THE IDAHO PUBLIC UTILITIES COMMISSION Pursuant to Commission Rules 212 and 213,1 Exelon Corporation (“Exelon”) submits this limited Answer to the Answer filed by the Idaho Public Utilities Commission (“Idaho PUC”) in this proceeding. Exelon submits that Ce

Copyright ©2010-2018 Medical Science